At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,904 enrolled
Drug / intervention
MK0653, ezetimibe +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg/Day When Added to Ongoing Therapy With a Statin Versus Statin Therapy Alone, in Patients With Hypercholesterolemia Who Have Not Reached National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Target LDL-Cholesterol Level
In Brief
A Phase 3 clinical trial evaluating MK0653, ezetimibe and Comparator: statins for Hypercholesterolemia. Completed, enrolled 2,904 participants.
Detailed Summary
The purpose of this 6-week study is to compare the reduction in specific levels of cholesterol in patients with high cholesterol.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2002
Primary CompletionOct 2003
First PostedSep 2004
TodayJul 2026
First PostedSep 28, 2004
Enrollment StartSep 1, 2002
Primary CompletionOct 1, 2003
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 21.8 years ago
Interventions
MK0653, ezetimibedrug
Comparator: statinsdrug